Updates are available Correction dated 2023-08-03
Click to view Correction: https://doi.org/10.1007/s41669-023-00434-x
-
Authors
Bromilow, Tom http://orcid.org/0000-0003-2494-5685
Holmes, Hayden
Coote, Laura
Woods, Sam
Pink, Joshua
- License Information
-
More Information
Article History
Accepted: 3 May 2023
First Online: 12 June 2023
Change Date: 3 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s41669-023-00434-x
Declarations
:
: The guideline referred to in this article was produced by the NICE. The views expressed in this article are those of the authors and not necessarily those of NICE (2021; Clostridioides difficile infection: antimicrobial prescribing. Available at ExternalRef removed).
: The authors received no financial support for the research, authorship, and/or publication of this article. York Health Economics Consortium received payment from NICE to undertake the underlying analysis.
: Tom Bromilow, Hayden Holmes, Laura Coote, Sam Woods, and Joshua Pink declare that they have no conflicts of interest to report.
: Not applicable.
: Not applicable.
: Not applicable.
: The efficacy data used to inform the model parameters have been previously published by Beinortas et al. [CitationRef removed]. The health economic model has been shared as part of the electronic supplementary material.
: Not applicable.
: TB, HH and JP conceptualised the model and wrote the model protocol. TB and HH built and finalised the model. JP and HH reviewed and critiqued the final model and its associated results. LC and SW wrote the manuscript, with review and input from TB, HH and JP.
